Dr. med. Dirk Manski



 You are here: Urology Textbook > Drugs in Urology > Antibiotics > Norfloxacin


Norfloxacin: Side Effects, Contraindications and Dosage

Review literature: (Simon und Stille, 1997).

Mechanism of Action of Norfloxacin

Norfloxacin is a fluoroquinolone antibiotic, which interferes with the bacterial DNA synthesis via inhibition of the DNA gyrase or topoisomerase II. Fluoroquinolone antibiotics are bactericidal.

Indications for Norfloxacin

Norfloxacin is active against a variety of bacteria:

Urologic indications for norfloxacin are urinary tract infections, prostatitis, acute pyelonephritis, epididymitis or perioperative antibiotic prophylaxis for transurethral surgery.

Pharmacokinetics of Norfloxacin

Side Effects of Norfloxacin

Interactions with Norfloxacin:

Do not give nitrofurantoin, iron salts, magnesium or aluminum-containing antacids together with norfloxacin. Increased concentrations of theophyllin or ciclosporin due to norfloxacin administration. Norfloxacin increases increases warfarin effect.

Contraindications to Norfloxacin

Dosage of Norfloxacin

Normal dosage of norfloxacin is 400 mg 1-0-1 p.o. Dose reduction to 400 mg 1-0-0 is necessary in impaired renal function (GFR below 30 ml/min).







Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



References

Auquer u.a. 2002 AUQUER, F. ; CORDON, F. ; GORINA, E. ; CABALLERO, J. C. ; ADALID, C. ; BATLLE, J.:
Single-dose ciprofloxacin versus 3 days of norfloxacin in uncomplicated urinary tract infections in women.
In: Clin Microbiol Infect
8 (2002), Nr. 1, S. 50–4

Henry u.a. 2002 HENRY, Jr. ; BETTIS, R. B. ; RIFFER, E. ; HAVERSTOCK, D. C. ; KOWALSKY, S. F. ; MANNING, K. ; HAMED, K. A. ; CHURCH, D. A.:
Comparison of once-daily extended-release ciprofloxacin and conventional twice-daily ciprofloxacin for the treatment of uncomplicated urinary tract infection in women.
In: Clin Ther
24 (2002), Nr. 12, S. 2088–104

Krcmery und Naber 1999 KRCMERY, S. ; NABER, K. G.:
Ciprofloxacin once versus twice daily in the treatment of complicated urinary tract infections. German Ciprofloxacin UTI Study Group.
In: Int J Antimicrob Agents
11 (1999), Nr. 2, S. 133–8

Martin u.a. 1998 MARTIN, S. J. ; MEYER, J. M. ; CHUCK, S. K. ; JUNG, R. ; MESSICK, C. R. ; PENDLAND, S. L.:
Levofloxacin and sparfloxacin: new quinolone antibiotics.
In: Ann Pharmacother
32 (1998), Nr. 3, S. 320–36

Mombelli u.a. 1999 MOMBELLI, G. ; PEZZOLI, R. ; PINOJA-LUTZ, G. ; MONOTTI, R. ; MARONE, C. ; FRANCIOLLI, M.:
Oral vs. intravenous ciprofloxacin in the initial empirical management of severe pyelonephritis or complicated urinary tract infections: a prospective randomized clinical trial.
In: Arch Intern Med
159 (1999), Nr. 1, S. 53–8

Naber u.a. 1999 NABER, K. G. ; THEURETZBACHER, U. ; MONEVA-KOUCHEVA, G. ; STASS, H.:
Urinary excretion and bactericidal activity of intravenous ciprofloxacin compared with oral ciprofloxacin.
In: Eur J Clin Microbiol Infect Dis
18 (1999), Nr. 11, S. 783–9

Raz u.a. 2000 RAZ, R. ; NABER, K. G. ; RAIZENBERG, C. ; ROHANA, Y. ; UNAMBA-OPARAH, I. ; KORFMAN, G. ; YANIV, I.:
Ciprofloxacin 250 mg twice daily versus ofloxacin 200 mg twice daily in the treatment of complicated urinary tract infections in women.
In: Eur J Clin Microbiol Infect Dis
19 (2000), Nr. 5, S. 327–31

Reid u.a. 2000 REID, G. ; POTTER, P. ; DELANEY, G. ; HSIEH, J. ; NICOSIA, S. ; HAYES, K.:
Ofloxacin for the treatment of urinary tract infections and biofilms in spinal cord injury.
In: Int J Antimicrob Agents
13 (2000), Nr. 4, S. 305–7

Simon und Stille 1997 SIMON, C. ; STILLE, W.:
Antibiotika-Therapie in Klinik und Praxis.
9. Auflage.
Stuttgart New York : Schattauer, 1997

Talan u.a. 2004 TALAN, D. A. ; KLIMBERG, I. W. ; NICOLLE, L. E. ; SONG, J. ; KOWALSKY, S. F. ; CHURCH, D. A.:
Once daily, extended release ciprofloxacin for complicated urinary tract infections and acute uncomplicated pyelonephritis.
In: J Urol
171 (2004), Nr. 2 Pt 1, S. 734–9


  Deutsche Version: Nebenwirkungen, Kontraindikationen und Dosierung von Norfloxacin